NASDAQ:PACB

Pacific Biosciences of California Stock Forecast, Price & News

$13.28

-0.69 (-4.94 %)

(As of 10/29/2020 03:40 PM ET)

Add

Compare

Today's Range

$13.28

Now: $13.28▼

$14.19

50-Day Range

$6.51

MA: $10.96▼

$14.95

52-Week Range

$2.20

Now: $13.28▼

$15.12

Volume137,484 shs

Average Volume2.57 million shs

Market Capitalization$2.05 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.7

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Beat the Market (BTM) Rank^™

1.4 Analyst's Opinion

Consensus Rating
Pacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.60, Pacific Biosciences of California has a forecasted downside of 15.8% from its current price of $13.78.
Amount of Analyst Coverage
Pacific Biosciences of California has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Pacific Biosciences of California has received 417 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Pacific Biosciences of California has received 336 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Pacific Biosciences of California has received 55.38% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote “Outperform” if you believe PACB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Pacific Biosciences of California does not currently pay a dividend.
Dividend Growth
Pacific Biosciences of California does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,624,328.00 in company stock.
Percentage Held by Insiders
Only 11.60% of the stock of Pacific Biosciences of California is held by insiders.
Percentage Held by Institutions
72.46% of the stock of Pacific Biosciences of California is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Pacific Biosciences of California are expected to decrease in the coming year, from ($0.38) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pacific Biosciences of California is -41.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pacific Biosciences of California is -41.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pacific Biosciences of California has a P/B Ratio of 38.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.04 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryLife Sciences Tools & Services

SectorMedical

Current SymbolNASDAQ:PACB

Previous Symbol

CUSIP69404D10

CIK1299130

Webwww.pacb.com

Phone650-521-8000

Employees401

Debt

Debt-to-Equity RatioN/A

Current Ratio1.15

Quick Ratio1.03

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$90.89 million

Price / Sales22.56

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.36 per share

Price / Book36.89

Profitability

EPS (Most Recent Fiscal Year)($0.55)

Net Income$-84,130,000.00

Net Margins-61.85%

Return on Equity-150.00%

Return on Assets-41.97%

Miscellaneous

Outstanding Shares154,409,000

Market Cap$2.05 billion

Next Earnings Date11/2/2020 (Confirmed)

OptionableOptionable

$13.28

-0.69 (-4.94 %)

(As of 10/29/2020 03:40 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

How has Pacific Biosciences of California's stock price been impacted by COVID-19 (Coronavirus)?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PACB stock has increased by 286.0% and is now trading at $13.28.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Pacific Biosciences of California?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pacific Biosciences of California.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Pacific Biosciences of California.

How can I listen to Pacific Biosciences of California's earnings call?

Pacific Biosciences of California will be holding an earnings conference call on Monday, November 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings data on Monday, August, 3rd. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.04. The biotechnology company earned $17.08 million during the quarter, compared to analysts' expectations of $13.84 million. Pacific Biosciences of California had a negative net margin of 61.85% and a negative return on equity of 150.00%.
View Pacific Biosciences of California's earnings history.

What price target have analysts set for PACB?

5 analysts have issued 1-year target prices for Pacific Biosciences of California's shares. Their forecasts range from $7.00 to $17.00. On average, they anticipate Pacific Biosciences of California's share price to reach $11.60 in the next twelve months. This suggests that the stock has a possible downside of 12.7%.
View analysts' price targets for Pacific Biosciences of California.

Who are some of Pacific Biosciences of California's key competitors?

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), Charles River Laboratories International (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all competitors.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), InVitae (NVTA) and Tesla (TSLA).

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:

Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)
Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)
Mr. James Michael Phillips, Sr. VP of R&D (Age 68)
Dr. Stephen Turner, Co-Founder & CTO (Age 51)
Dr. Jonas Korlach Ph.D., Chief Scientific Officer

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.56%), Moloney Securities Asset Management LLC (0.05%), Archford Capital Strategies LLC (0.04%), Havens Advisors LLC (0.04%), Dynamic Advisor Solutions LLC (0.02%) and Cambridge Investment Research Advisors Inc. (0.01%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes.
View institutional ownership trends for Pacific Biosciences of California.

Which major investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including Havens Advisors LLC, Assenagon Asset Management S.A., and Moloney Securities Asset Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller, and Susan K Barnes.
View insider buying and selling activity for Pacific Biosciences of California.

Which major investors are buying Pacific Biosciences of California stock?

PACB stock was acquired by a variety of institutional investors in the last quarter, including Archford Capital Strategies LLC, Dynamic Advisor Solutions LLC, Cambridge Investment Research Advisors Inc., Nisa Investment Advisors LLC, and Clear Harbor Asset Management LLC.
View insider buying and selling activity for Pacific Biosciences of California.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $13.28.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $2.05 billion and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings